Literature DB >> 12847065

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.

Stefan K James1, Bertil Lindahl, Agneta Siegbahn, Mats Stridsberg, Per Venge, Paul Armstrong, Elliot S Barnathan, Robert Califf, Eric J Topol, Maarten L Simoons, Lars Wallentin.   

Abstract

BACKGROUND: Biochemical markers are useful for prediction of cardiac events in patients with non-ST-segment-elevation acute coronary syndrome (ACS). The associations between N-terminal pro-brain natriuretic peptide (NT-proBNP) and other biochemical and clinical risk indicators, as well as their prognostic value concerning the individual end points of death and myocardial infarction (MI), were elucidated in a large cohort of ACS patients. METHODS AND
RESULTS: NT-proBNP, troponin T, and C-reactive protein (CRP) were analyzed in blood samples obtained at a median of 9.5 hours from symptom onset in 6809 of 7800 ACS patients in the Global Utilization of Strategies To Open occluded arteries-IV (GUSTO-IV) trial. Levels of NT-proBNP were correlated independently with age, female gender, low body weight, diabetes, renal dysfunction, history of MI, heart failure, heart rate, ongoing myocardial damage, and time since onset of ischemia. Increasing quartiles of NT-proBNP were related to short- and long-term mortality that reached 1.8%, 3.9%, 7.7%, and 19.2%, (P<0.001), respectively, at 1 year. Levels of troponin T, CRP, heart rate, and creatinine clearance, in addition to ST-segment depression, were also correlated independently with 1-year mortality, but NT-proBNP was the marker with the strongest relation. In contrast, only troponin T, creatinine clearance, and ST-segment depression were independently related to future MI. The combination of NT-proBNP and creatinine clearance provided the best prediction, with a 1-year mortality of 25.7% with both markers in the top quartile vs 0.3% with both markers in the bottom quartile.
CONCLUSIONS: The use of NT-proBNP appears to add critical prognostic insight to the assessment of patients with ACS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847065     DOI: 10.1161/01.CIR.0000079170.10579.DC

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  90 in total

1.  N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction.

Authors:  Justin A Ezekowitz; Pierre Théroux; Weiching Chang; Kenneth W Mahaffey; Christopher B Granger; W D Weaver; Judith S Hochman; Paul W Armstrong
Journal:  Can J Cardiol       Date:  2006-04       Impact factor: 5.223

Review 2.  Markers to define ischemia: are they ready for prime time use in patients with acute coronary syndromes?

Authors:  Jesse Adams
Journal:  Curr Cardiol Rep       Date:  2004-07       Impact factor: 2.931

Review 3.  Inflammatory and oxidative markers in atherosclerosis: relationship to outcome.

Authors:  Mehdi H Shishehbor; Stanley L Hazen
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

4.  Natriuretic peptides as markers of cardiovascular risk: the story continues.

Authors:  Hector O Ventura; Marc A Silver
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

5.  Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.

Authors:  Sean van Diepen; Matthew T Roe; Renato D Lopes; Amanda Stebbins; Stefan James; L Kristin Newby; David J Moliterno; Franz-Josef Neumann; Justin A Ezekowitz; Kenneth W Mahaffey; Judith S Hochman; Christian W Hamm; Paul W Armstrong; Pierre Theroux; Christopher B Granger
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 6.  Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes.

Authors:  Ankie Amos; L Kristin Newby
Journal:  Curr Cardiol Rep       Date:  2005-07       Impact factor: 2.931

Review 7.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

8.  Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements.

Authors:  Robert H Christenson; W H Wilson Tang
Journal:  MedGenMed       Date:  2006-05-31

9.  Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.

Authors:  L Tarnow; P Hildebrandt; B V Hansen; K Borch-Johnsen; H-H Parving
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

10.  The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.

Authors:  Hyo Jin Choi; Young Kee Shin; Hyun Joo Lee; Joo Young Kee; Dong Woo Shin; Eun Young Lee; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Clin Rheumatol       Date:  2007-09-25       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.